Levetiracetam Tablet, Film Coated, Extended Release
Product Images NDC 70518-4125

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 70518-4125). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Label for Levetiracetam ER 500 mg extended-release tablets, oral use, with a quantity of 30 tablets per package. The label shows the Remedyrpack Inc. logo and states the product is prescription only, listing the NDC 70518-4125-00. Manufactured by Westminster Pharma, the label includes storage instructions and a caution to keep medication out of reach of children.*

FDA Label Image

Chemical Structure (Levetiracetam 01)

Chemical structure of levetiracetam, showing its molecular framework including a pyrrolidone ring with associated functional groups.*

FDA Label Image

Figure 1 (Levetiracetam 02)

A vertical bar chart comparing the percentage of patients across three groups: placebo (7.4%), immediate-release levetiracetam 1,000 mg/day (37.1%), and immediate-release levetiracetam 3,000 mg/day (39.6%). The chart highlights statistically significant differences with asterisks for the levetiracetam groups versus placebo.*

FDA Label Image

Figure 2 (Levetiracetam 03)

A bar chart showing the percentage of patients experiencing a certain effect for placebo, immediate-release levetiracetam 1,000 mg/day, and immediate-release levetiracetam 2,000 mg/day groups. The y-axis indicates the percentage of patients, with values ranging from 0% to 45%. The placebo group (N=111) shows 6.3%, the 1,000 mg/day group (N=106) shows 20.8%, and the 2,000 mg/day group (N=105) shows 35.2%, with asterisks denoting statistical significance versus placebo.*

FDA Label Image

Figure 3 (Levetiracetam 04)

A bar chart comparing the percentage of patients responding to placebo versus immediate-release levetiracetam 3,000 mg/day. The x-axis shows two groups: placebo (N=104) and levetiracetam (N=180). The y-axis displays the percentage of patients, with placebo at 14.4% and levetiracetam at 39.4%. An asterisk indicates statistical significance versus placebo.*

FDA Label Image

Figure 4 (Levetiracetam 05)

A bar chart depicting the percentage of patients in two groups: Placebo (N=97) and Immediate-release levetiracetam (N=101). The chart shows 19.6% of patients in the placebo group and 44.6% in the immediate-release levetiracetam group, with an asterisk indicating statistical significance between the groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.